EUVIMEDEUVIMED entdecken
Crossref

Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide–Drug Conjugates for Targeted Cancer Therapy

Yang Zhang, Yiqing Fan, Shuyu Liu, Yonghui Guan, Jiale Wan, Qiang Ren, Jialing Wang, Li Zhong, Zhipeng Hu, Wei Shi, Hai Qian iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China. Hauptthemen laut MEDLINE: Peptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: State Key Laboratory of Natural Medicines, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-based targeted therapy in cancer faces a challenge due to uneven antibody distribution in solid tumors, hindering effective drug delivery. We addressed this by developing peptide mimetics with nanomolar-range affinity for Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using computational methods. These peptides showed both specific targeting and deep penetration in vitro and in vivo. Additionally, we created peptide-drug conjugates (PDCs) by linking targeting peptides to toxin drugs via various linkers and enhancing their in vivo half-life with fatty side chains for albumin binding. The antitumor candidate II-3 displayed exceptional affinity (KD = 1.72 × 10-9 M), internalization efficiency, anticancer potency (IC50 = 0.015 ± 0.002 μM), and pharmacokinetics (t1/2 = 2.6 h), showcasing a rational approach for designing PDCs with favorable tissue distribution and strong tumor penetration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidesHumansAnimalsMiceCell Line, TumorAntineoplastic AgentsImmunoconjugatesNeoplasmsFemaleMice, Inbred BALB C

Substanzen

PeptidesAntineoplastic AgentsImmunoconjugates

Autor:innen und Institutionen

  • Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
  • Department of Life Sciences, Changzhi University, Changzhi, Shanxi 046011, PR China.
  • Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, PR China.

ORCID-Profile: Hai Qian

Förderung

  • State Key Laboratory of Natural Medicines
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Fan, Y., Liu, S., Guan, Y., Wan, J., Ren, Q., Wang, J., Zhong, L., Hu, Z., Shi, W., & Qian, H. (2024). Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide–Drug Conjugates for Targeted Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00511

Vancouver

Zhang Y, Fan Y, Liu S, Guan Y, Wan J, Ren Q, et al. Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide–Drug Conjugates for Targeted Cancer Therapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00511

BibTeX
@article{Zhang2024,
  author = {Zhang, Yang and Fan, Yiqing and Liu, Shuyu and Guan, Yonghui and Wan, Jiale and Ren, Qiang and Wang, Jialing and Zhong, Li and Hu, Zhipeng and Shi, Wei and Qian, Hai},
  title = {Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide–Drug Conjugates for Targeted Cancer Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00511}
}
Kostenlos starten →